Adlai Nortye Ltd.
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E recept… Read more
Adlai Nortye Ltd. (N2U0) - Total Liabilities
Latest total liabilities as of December 2024: €45.78 Million EUR
Based on the latest financial reports, Adlai Nortye Ltd. (N2U0) has total liabilities worth €45.78 Million EUR as of December 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Adlai Nortye Ltd. - Total Liabilities Trend (2021–2024)
This chart illustrates how Adlai Nortye Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Adlai Nortye Ltd. Competitors by Total Liabilities
The table below lists competitors of Adlai Nortye Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Exel Composites Oyj
HE:EXL1V
|
Finland | €61.14 Million |
|
Hammond Manufacturing Company Limited
PINK:HMFAF
|
USA | $97.16 Million |
|
Bourse Direct SA
PA:BSD
|
France | €1.20 Billion |
|
J.G.CHEMICALS LIMITED
NSE:JGCHEM
|
India | ₹282.86 Million |
|
Ariana Resources Plc
AU:AA2
|
Australia | AU$2.48 Million |
|
Patria Latin American Opportunity Acquisition Corp
NASDAQ:PLAOU
|
USA | $25.76 Million |
Liability Composition Analysis (2021–2024)
This chart breaks down Adlai Nortye Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.41 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.80 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.64 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Adlai Nortye Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Adlai Nortye Ltd. (2021–2024)
The table below shows the annual total liabilities of Adlai Nortye Ltd. from 2021 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | €45.78 Million | -16.97% |
| 2023-12-31 | €55.14 Million | -82.43% |
| 2022-12-31 | €313.89 Million | -1.02% |
| 2021-12-31 | €317.11 Million | -- |